August 27th, 2008
University of Oklahoma researchers are working on a high-tech breath test that could one day help detect cancer.
The team is using mid-infrared laser technology to measure suspected cancer biomarkers in the breath, such as ethane, formaldehyde, and acetaldehyde, and to establish the relationship between those gas molecules and the disease. Ultimately, they hope their work will lead to easy-to-use detection devices that don’t emit radiation.
August 27th, 2008
Stand Up For A Cure’s 2008 Concert Series will continue its successful run on September 10th with a performance by Grammy(R)-winning Dave Matthews Band at Madison Square Garden. The charity confirmed today that the exclusive event will be hosted by Julia Roberts and will be preceded by a private VIP pre-show party featuring DJ Samantha Ronson.
New York-based non-profit, Stand Up For A Cure created the 2008 Concert Series as a year-long effort to raise funds and awareness for
lung cancer research and treatment. Last February, Bon Jovi was the first to perform in the Series of exclusive, private shows, which has included performances by Jerry Seinfeld and Brian Wilson. The Series has been made possible by sponsors and private donors.
August 26th, 2008
Risk for lung, colon and breast tumors is doubled, researchers say
August 26th, 2008
The repeated use of antibiotics has been linked to a higher risk of developing cancer, according to a study by the National Public Health Institute.
August 26th, 2008
The First European Lung Cancer Conference, held in Geneva and hosting many of the world’s leading medical experts, was the setting for an award ceremony held by the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO) to bestow their highest honor to a leading figure in the field of oncology.
Professor Heine H. Hansen, a luminary in the field of lung cancer research, was named the first recipient of IASLC-ESMO Lifetime Achievement Award for his outstanding contributions to medical science.
August 26th, 2008
Early cancer detection can significantly improve survival rates. Current diagnostic tests often fail to detect cancer in the earliest stages and at the same time expose a patient to the harmful effects of radiation. Led by Dr. Patrick McCann, a small group of internationally known researchers at the University of Oklahoma with expertise in the development of mid-infrared lasers is working to create a sensor to detect biomarker gases exhaled in the breath of a person with cancer.
August 25th, 2008
People from nonwhite backgrounds who have advanced-stage cancers are more likely to experience consistent and breakthrough chronic pain than their white counterparts, according to the results of the first prospective longitudinal study with a diverse population of men and women with advanced cancer
August 25th, 2008
What do Neiman Marcus, Bergdorf Goodman and the Bonnie J. Addario Lung Cancer Foundation have in common? Jessica Kagan Cushman. Introducing the new Bonnie J. Addario Lung Cancer Foundation LUNGSTORE with a BANGle! We’ve steered clear of the multi-colored rubber wristbands for a reason. Lung Cancer is too important and when the rubber meets the road…it deserves a store filled with SIMPLY THE BEST, most desirable, and eye-catching inventory. Stay tuned for new items as our store expands.
August 25th, 2008
Human Genome Sciences has completed enrollment and initial dosing of patients in a randomized Phase II trial of HGS-ETR1 in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
The non-small cell lung cancer (NSCLC) trial is a randomized, multi-center, open-label Phase II study to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and paclitaxel as first-line therapy in the treatment of advanced non-small cell lung cancer (Stage IIIB or IV).
August 25th, 2008
Many of the therapies are still in clinical trials, and research is limited on handling side effects and determining proper dosage. Through their work with patients, nurses can help determine which patients benefit most from which drugs and in what amounts. This data can help control the considerable costs. One of the most popular targeted therapies, Avastin, when used for metastatic breast cancer, can cost $7,700 per month wholesale. Tarceva, when used for lung cancer, can cost $3,375 per month, says a spokesperson for pharmaceutical company Genentech. Nurses may need to work with pharmacies, social workers, and insurance companies to determine how a patient will pay for the treatments.